title: Is vitamin K1 supplementation necessary in long-term parenteral nutrition?
abstract: BACKGROUND
  I.v. lipid emulsions contain vitamin K in substantial quantities and in 1989, we therfore stopped supplying vitamin K1 to patients receiving home parenteral nutrition (HPN).
  
  
  METHODS
  Nine patients (group I) receiving HPN before 1989 (10 mg i.v. vitamin K1 supplementation weekly until 1989, which was discontinued thereafter) and six patients with an initial low plasma vitamin K1 concentration (related to their malabsorption) (group II) receiving HPN after 1989 were studied. Prothrombin time (PT), plasma vitamin K1 concentration, and vitamin K1, content in lipid emulsions were measured throughout the period of HPN.
  
  
  RESULTS
  All lipid emulsions, except for Eurolip 20% and Clinoleic 20% (Baxter SA, Maurepas, France) contained vitamin K1, with concentration ranges from 179 +/- 39 to 353 +/- 78 ng/L. Group I patients had an initial high plasma vitamin K1 concentration due to the vitamin K1 supplementation. After this supplementation was discontinued, plasma vitamin K1 decreased and remained in normal ranges with a normal PT. Throughout the HPN period after 1989, patients received 255 +/- 104 micrograms of vitamin K1 weekly through lipid emulsions. The PT and plasma vitamin K1 concentrations in group II patients were restored by lipid emulsions, which contained 418 +/- 143 micrograms/wk of vitamin K1.
  
  
  CONCLUSIONS
  In patients receiving i.v. lipids (except for Eurolip and Clinoleic), a normal vitamin K1 status can be maintained during long-term HPN without vitamin K1 supplementation. However, vitamin K supplementation cannot be abandoned until the vitamin K content of emulsions is standardized by manufacturers. A weekly supply of 250 to 400 micrograms of vitamin K1 is enough to maintain and even restore a normal vitamin K1 status in HPN.
authors.affiliation: Unité de Nutrition Artificielle, Hotel Dieu, Lyon, France.
authors.forename: C
authors.initials: C
authors.lastname: Chambrier
authors.forename: M
authors.initials: M
authors.lastname: Leclercq
authors.forename: F
authors.initials: F
authors.lastname: Saudin
authors.forename: B
authors.initials: B
authors.lastname: Vignal
authors.forename: S
authors.initials: S
authors.lastname: Bryssine
authors.forename: M
authors.initials: M
authors.lastname: Guillaumont
authors.forename: P
authors.initials: P
authors.lastname: Bouletreau
mesh_terms: D000328:Adult; D000368:Aged; D015331:Cohort Studies; D005217:Fat Emulsions, Intravenous / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007410:Intestinal Diseases / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016331:Parenteral Nutrition, Home / Q000379:methods*; D011517:Prothrombin Time; D012189:Retrospective Studies; D013997:Time Factors; D014812:Vitamin K / Q000008:administration & dosage* / Q000097:blood / Q000378:metabolism
chemical_list: D005217:Fat Emulsions, Intravenous; D014812:Vitamin K